Cue Biopharma Price To Book vs. Return On Asset
| CUE Stock | USD 1.02 0.01 0.97% |
For Cue Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cue Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cue Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cue Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cue Biopharma over time as well as its relative position and ranking within its peers.
Cue |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cue Biopharma Return On Asset vs. Price To Book Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cue Biopharma's current stock value. Our valuation model uses many indicators to compare Cue Biopharma value to that of its competitors to determine the firm's financial worth. Cue Biopharma is rated below average in price to book category among its peers. It is rated below average in return on asset category among its peers . As of November 23, 2024, Return On Assets is expected to decline to -0.87. Comparative valuation analysis is a catch-all technique that is used if you cannot value Cue Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cue Return On Asset vs. Price To Book
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Cue Biopharma |
| = | 2.55 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Cue Biopharma |
| = | -0.52 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Cue Return On Asset Comparison
Cue Biopharma is currently under evaluation in return on asset category among its peers.
Cue Biopharma Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cue Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cue Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Cue Biopharma's change in net profit over the period of time. It can combine multiple indicators of Cue Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -110.3 K | -115.8 K | |
| Operating Income | -52.1 M | -54.8 M | |
| Net Loss | -50.7 M | -53.3 M | |
| Income Before Tax | -50.7 M | -53.3 M | |
| Total Other Income Expense Net | 1.4 M | 1.5 M | |
| Net Loss | -47.7 M | -50.1 M | |
| Net Loss | -50.7 M | -53.3 M | |
| Income Tax Expense | 3.3 M | 3.4 M | |
| Net Interest Income | 1.4 M | 1.5 M | |
| Interest Income | 2.7 M | 2.8 M | |
| Non Operating Income Net Other | 57.7 K | 91.8 K | |
| Change To Netincome | 10.9 M | 7.4 M | |
| Net Loss | (1.11) | (1.16) | |
| Income Quality | 0.79 | 0.61 | |
| Net Income Per E B T | 1.15 | 1.11 |
Cue Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cue Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cue Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cue Biopharma's important profitability drivers and their relationship over time.
Use Cue Biopharma in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cue Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cue Biopharma will appreciate offsetting losses from the drop in the long position's value.Cue Biopharma Pair Trading
Cue Biopharma Pair Trading Analysis
The ability to find closely correlated positions to Cue Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cue Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cue Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cue Biopharma to buy it.
The correlation of Cue Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cue Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cue Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cue Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cue Biopharma position
In addition to having Cue Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Business Services Thematic Idea Now
Business Services
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Services theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Services Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
To fully project Cue Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cue Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cue Biopharma's income statement, its balance sheet, and the statement of cash flows.